Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren Dose-finding in Essential Hypertension
NCT00311012Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aliskiren in essential hypertension (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in mean sitting diastolic blood pressure at 8 weeks. Started Aug 2004; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00311012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311012.